Download May 6, 2014 - Current Oncology

May 23, 2014
Martin Chasen, MBChB FCP(SA) MPhil(Pall Med)
Managing Editor, Current Oncology
University of Ottawa and Elizabeth Bruyere Hospital
Ottawa, ON, Canada
Dear Dr. Chasen:
Thank you for considering our manuscript, entitled “Hsp90 Inhibitors in Oncology:
Ready for Prime Time?” for publication in the Commentaries section of Current
Oncology as per previous e-mail correspondence (October 2013).
The goal of our manuscript is to review the recent updates in the early phase
clinical trial development of Hsp90 inhibitors, specifically with three promising
Hsp90 inhibitors (retaspimycin, ganetespib, AUY-992). We feel that this topic is
particularly relevant in solid tumours including non-small cell lung cancer
(NSCLC) especially with results presented at the World Conference on Lung
Cancer in the Fall of 2013 from GALAXY-1 (evaluating ganetespib with docetaxel
in advanced non-small cell lung adenocarcinoma) which demonstrated a robust
improvement in median PFS and OS. In addition, there is also encouraging data
with the use of Hsp90 inhibitors in solid tumour subsets such as EGFR or ALK
positive NSCLC, as well as HER-2 positive metastatic breast cancer.
I look forward to your comments and feedback.
Sincerely,
Roger Y. Tsang, MD, FRCPC
Clinical Assistant Professor, University of Calgary
Medical Oncologist, Tom Baker Cancer Centre
Calgary, AB, Canada